Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-dose safety, drug-drug interaction, and pharmacokinetics study of TBD11 in healthy adults
PACTR202610906813722Phase 1Not yet recruiting
- Sponsor
- Gates Medical Research Institute
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1 trial of Tat-beclin 1 D11 in Tuberculosis (TB) (4 cohorts), sponsored by Gates Medical Research Institute. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Tat-beclin 1 D11
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202610906813722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610906813722.